- Home
- MRBK vs TCRX Comparison
MRBK vs TCRX Comparison
Compare MRBK & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- TCRX
- Stock Information
- Founded
- MRBK 2004
- TCRX 2018
- Country
- MRBK United States
- TCRX United States
- Employees
- MRBK N/A
- TCRX N/A
- Industry
- MRBK Major Banks
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MRBK Finance
- TCRX Health Care
- Exchange
- MRBK Nasdaq
- TCRX Nasdaq
- Market Cap
- MRBK 162.3M
- TCRX 140.7M
- IPO Year
- MRBK 2017
- TCRX 2021
- Fundamental
- Price
- MRBK $14.74
- TCRX $2.09
- Analyst Decision
- MRBK Buy
- TCRX Strong Buy
- Analyst Count
- MRBK 2
- TCRX 5
- Target Price
- MRBK $17.50
- TCRX $9.40
- AVG Volume (30 Days)
- MRBK 53.9K
- TCRX 768.1K
- Earning Date
- MRBK 10-23-2025
- TCRX 11-07-2025
- Dividend Yield
- MRBK 3.38%
- TCRX N/A
- EPS Growth
- MRBK 75.95
- TCRX N/A
- EPS
- MRBK 1.77
- TCRX N/A
- Revenue
- MRBK $109,758,000.00
- TCRX $6,961,000.00
- Revenue This Year
- MRBK $25.14
- TCRX $255.18
- Revenue Next Year
- MRBK $8.08
- TCRX N/A
- P/E Ratio
- MRBK $8.34
- TCRX N/A
- Revenue Growth
- MRBK 18.84
- TCRX N/A
- 52 Week Low
- MRBK $11.16
- TCRX $1.02
- 52 Week High
- MRBK $17.33
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- MRBK 46.44
- TCRX 48.17
- Support Level
- MRBK $14.62
- TCRX $2.23
- Resistance Level
- MRBK $15.79
- TCRX $2.43
- Average True Range (ATR)
- MRBK 0.55
- TCRX 0.18
- MACD
- MRBK 0.05
- TCRX -0.03
- Stochastic Oscillator
- MRBK 46.97
- TCRX 12.61
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.